Study of cabotegravir and lenacapavir for HIV treatment
Part of Infections clinical trials.
This study follows people with HIV who are starting or have recently started a treatment using two long-acting medications, cabotegravir and lenacapavir. It aims to see how well this combination works in real life, which could help improve care for others.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You must be living with HIV-1 (the most common type of HIV)
- You must have started or plan to start the combination of cabotegravir and lenacapavir (two long-acting HIV medicines) between July 2024 and one year after starting
- Your doctor must have decided that this combination is right for you
- You must agree to allow the study team to use your medical data for follow-up (your details stay private)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well lenacapavir works when added to a personalized HIV treatment plan. If you have HIV and received lenacapavir as your first dose between June 2023 and June 2024, this research may help understand its real-world effects.
This study follows adults with well-controlled HIV who are planning to switch to a long-acting HIV medicine given as injections. It may help researchers understand how this approach works for people already stable on current treatment.
This trial provides cabotegravir, a long-acting injectable HIV medicine, for people who cannot take or absorb oral HIV medications. It is for those who have no other effective treatment options.
This trial tests a new medication, lenacapavir, to see how well it works for preventing HIV. It is for people who want or need PrEP (a medicine to prevent HIV) and are interested in learning about different options.
This phase 3 trial tests a new long-acting, injectable two-drug combination (lenacapavir + teropavimab + zinlirvimab) vs. another injectable combo (cabotegravir + rilpivirine) for people whose HIV is already well-controlled on daily oral meds. It aims to see if the new combo can keep the virus under control with fewer injections.
This study looks at how long an injectable HIV treatment (cabotegravir and rilpivirine) keeps working in people whose virus is already well controlled. It aims to see the real-world experience and how long patients stay on this treatment.
Hear when a new CABOTEGRAVIR trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.